Wedbush analyst Laura Chico raised the firm’s price target on Neurocrine to $137 from $120 and keeps an Outperform rating on the shares. With the adult Phase 3 CAHtalyst study meeting its primary and key secondary endpoints, the firm is incorporating credit for crinecerfont in its Neurocrine estimates. Wedbush continues to await top-line results in the pediatric CAH setting and leaves this as a call option.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NBIX:
- Neurocrine price target raised to $111 from $100 at BMO Capital
- Neurocrine announces ‘positive’ data from Phase 3 study of crinecerfont
- Neurocrine initiates Phase 1 study of NBI-1117570
- Neurocrine’s Ingrezza shows improvement in tardive dyskinesia study
- Neurocrine presents new INGREZZA capsules data
